Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2019; 11(04): 335-339
DOI: 10.4103/JLP.JLP_168_18
Original Article

Serum soluble FMS-like tyrosine kinase-1 in ectopic pregnancy

Sathya Selvarajan
Department of Biochemistry, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India
,
Jothimalar Ramalingam
Department of Biochemistry, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India
,
Jaya Vijayaraghavan
Department of Obstetrics and Gynaecology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India
,
Zachariah Bobby
Department of Biochemistry, JIPMER, Puducherry, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

CONTEXT: The diagnosis of an ectopic pregnancy (EP) requires the usage of serial beta-human chorionic gonadotropin (hCG) measurements and ultrasonography to locate the gestational sac. With the rising trends in its incidence, a rapid, noninvasive biomarker to detect this condition at the earliest can aid in decreasing the morbidity and mortality linked with EP.

AIMS: This study was performed to determine the serum level of soluble FMS-like tyrosine kinase-1 (sFLT-1) at 4–10-week gestation in EP and normal pregnancy and to identify whether it can be used as a biomarker to distinguish an EP from a normal intrauterine pregnancy.

SETTINGS AND DESIGN: This was a prospective case–control study conducted over 2 years from 2015 to 2017 in 280 women between the age groups of 19 and 38 years at a tertiary level hospital.

SUBJECTS AND METHODS: Levels of sFLT-1 in sera of 140 women with EP and 140 women with normal pregnancy were assayed by a sandwich enzyme-linked immunosorbent assay at Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu, India.

STATISTICAL ANALYSIS USED: Statistical analyses were performed with SPSS software version 16.0, and P ≤ 0.05 was considered statistically significant.

RESULTS: The median sFLT-1 level in EP was 419 pg/ml. This was significantly lower than the value of 898 pg/ml in normal pregnancy. Receiver operating characteristic curve analysis showed that at a cutoff of 623 pg/ml, sFLT-1 was able to distinguish an EP from a normal intrauterine pregnancy with a sensitivity of 98.6% and a specificity of 90.7%.

CONCLUSIONS: The present study showed the significant early lowering of sFLT-1 in EP and may be considered as an effective biomarker compared to beta-hCG.

Key words

Beta-human chorionic gonadotropin - biomarker - diagnostic test - ectopic pregnancy - gestational age - normal pregnancy - sensitivity - serum sFLT-1 concentration - specificity


Publication History

Received: 10 December 2018

Accepted: 24 August 2019

Article published online:
07 April 2020

© 2019.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Walker JJ. Ectopic pregnancy. Clin Obstet Gynecol 2007;50:89-99.
  • 2 Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol 2010;116:1302-9.
  • 3 Alkatout I, Honemeyer U, Strauss A, Tinelli A, Malvasi A, Jonat W, et al. Clinical diagnosis and treatment of ectopic pregnancy. Obstet Gynecol Surv 2013;68:571-81.
  • 4 Li C, Zhao WH, Zhu Q, Cao SJ, Ping H, Xi X, et al. Risk factors for ectopic pregnancy: A multi-center case-control study. BMC Pregnancy Childbirth 2015;15:187.
  • 5 Zhang D, Shi W, Li C, Yuan JJ, Xia W, Xue RH, et al. Risk factors for recurrent ectopic pregnancy: A case-control study. BJOG 2016;123 Suppl 3:82-9.
  • 6 Condous G, Van Calster B, Kirk E, Haider Z, Timmerman D, Van Huffel S, et al. Prediction of ectopic pregnancy in women with a pregnancy of unknown location. Ultrasound Obstet Gynecol 2007;29:680-7.
  • 7 Barnhart KT, Katz I, Hummel A, Gracia CR. Presumed diagnosis of ectopic pregnancy. Obstet Gynecol 2002;100:505-10.
  • 8 Rajendiren S, Dhiman P. Biomarkers of ectopic pregnancy-present and future. In: Darwish A, editor. Contemporary Gynecologic Practice. India: In Tech; 2015. p. 2.
  • 9 Zarezade N, Saboori Darabi S, Ramezanali F, Amirchaghmaghi E, Khalili G, Moini A, et al. mRNA expression of VEGF and its receptors in fallopian tubes of women with ectopic pregnancies. Int J Fertil Steril 2015;9:55-64.
  • 10 Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998;59:1540-8.
  • 11 Shibuya M. Vascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 2013;153:13-9.
  • 12 Lam PM, Briton-Jones C, Cheung CK, Leung SW, Cheung LP, Haines C. Increased messenger RNA expression of vascular endothelial growth factor and its receptors in the implantation site of the human oviduct with ectopic gestation. Fertil Steril 2004;82:686-90.
  • 13 Felemban A, Sammour A, Tulandi T. Serum vascular endothelial growth factor as a possible marker for early ectopic pregnancy. Hum Reprod 2002;17:490-2.
  • 14 Daponte A, Pournaras S, Polyzos NP, Tsezou A, Skentou H, Anastasiadou F, et al. Soluble FMS-like tyrosine kinase-1 (sFlt-1) and serum placental growth factor (PlGF) as biomarkers for ectopic pregnancy and missed abortion. J Clin Endocrinol Metab 2011;96:E1444-51.
  • 15 Martínez-Ruiz A, Sarabia-Meseguer MD, Pérez-Fornieles J, Vílchez JA, Tovar-Zapata I, Noguera-Velasco JA. Placental growth factor, soluble fms-like tyrosine kinase 1 and progesterone as diagnostic biomarkers for ectopic pregnancy and missed abortion. Clin Biochem 2014;47:844-7.
  • 16 Richardson A, Deb S, Campbell B, Raine-Fenning N. Serum concentrations of Ang-2 and Flt-1 may be predictive of pregnancy outcome in women with pregnancies of uncertain viability: A phase I exploratory prognostic factor study. J Obstet Gynaecol 2018;38:321-6.